NewAmsterdam Pharma vs ProQR Therapeutics
NAMS and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAMS and PRQR compare
ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −88.9% for NewAmsterdam Pharma).
ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −3644% at NewAmsterdam Pharma.
ProQR Therapeutics scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAMS | PRQR |
|---|---|---|
| Size and price | ||
| Share price | $19.39 | $1.15 |
| Change, 1 year | −49.4% | −47.0% |
| Change, 5 years | 98.1% | −84.0% |
| Beta (5Y) | 1.57 | 2.58 |
| Employees | 100 | 59 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −88.9% | 11.4% (better) |
| Profitability | ||
| Operating margin | −3432% | −233% (better) |
| Net margin | −3644% | −229% (better) |
| FCF margin | −2018% | −273% (better) |
| Return on equity | −36.8% (better) | −57.4% |
| Return on invested capital | −1046% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.06 (better) |
| Current ratio | 9.03 (better) | 3.49 |
| Piotroski F-score | 3 (better) | 1 |
| Ownership | ||
| Held by institutions | – | 57.6% |
| Held by insiders | 22.0% | 37.8% |
| Insider net buying, 12 months | −$63.0M | $1.3M (better) |
Go deeper
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.